Autopsy report · NCT00097344

The CAT Study: Atamestane Plus Toremifene Versus Letrozole in Advanced Breast Cancer

Cause of deathFutility Automatic label, confidence 0.5, unverified. How labels are made.

“Identical study Biomed 777-CLP-029 did not meet superiority endpoint”

The sponsor’s own words in the registry.

Life of this trial

Ran for about 1 year 8 months before it stopped.
842 participants enrolled.
No results are posted on the registry.

Vital statistics

Status: Terminated
Phase: Phase 3
Sponsor: Intarcia Therapeutics
Sponsor type: Industry
Conditions: Breast Neoplasms; Neoplasms, Hormone-Dependent
Interventions: Atamestane; Toremifene; Letrozole; Aromatase inhibition; Estrogen receptor blocker; Hormone therapy
Participants: 842
Sites: 104
Countries: Bulgaria, Romania, Russia, Ukraine, United States

Look deeper

The official registry record (the source of truth)
Record history: every change the sponsor made
Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.